Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ARS Pharmaceuticals, Inc. - Common Stock
(NQ:
SPRY
)
13.33
-0.21 (-1.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,083,923
Open
13.65
Bid (Size)
13.33 (1)
Ask (Size)
13.39 (1)
Prev. Close
13.54
Today's Range
13.27 - 13.72
52wk Range
2.550 - 13.72
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
August 13, 2024
Via
Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
August 09, 2024
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,...
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+138.89%
+138.89%
1 Month
+26.47%
+26.47%
3 Month
+45.05%
+45.05%
6 Month
+77.26%
+77.26%
1 Year
+90.16%
+90.16%
More News
Read More
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
August 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
August 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
June 28, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
May 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
April 03, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
March 28, 2024
Via
Benzinga
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
March 21, 2024
Via
InvestorPlace
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
March 15, 2024
Via
InvestorPlace
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
March 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
March 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
February 26, 2024
Via
Benzinga
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
February 26, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
February 22, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
February 20, 2024
Via
Benzinga
Exposures
Product Safety
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
February 20, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
February 05, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 10, 2023
Via
Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
November 10, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.